These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 27856730)

  • 41. Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States.
    Sader HS; Huband MD; Castanheira M; Flamm RK
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069652
    [No Abstract]   [Full Text] [Related]  

  • 42. Carbapenem-resistant Pseudomonas aeruginosa: factors influencing multidrug-resistant acquisition in non-critically ill patients.
    Peña C; Suarez C; Tubau F; Dominguez A; Sora M; Pujol M; Gudiol F; Ariza J
    Eur J Clin Microbiol Infect Dis; 2009 May; 28(5):519-22. PubMed ID: 18949495
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Activity of newest generation β-lactam/β-lactamase inhibitor combination therapies against multidrug resistant Pseudomonas aeruginosa.
    Haines RR; Putsathit P; Hammer KA; Tai AS
    Sci Rep; 2022 Oct; 12(1):16814. PubMed ID: 36207358
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa.
    Tam VH; Chang KT; Abdelraouf K; Brioso CG; Ameka M; McCaskey LA; Weston JS; Caeiro JP; Garey KW
    Antimicrob Agents Chemother; 2010 Mar; 54(3):1160-4. PubMed ID: 20086165
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Risk Factors and Outcomes of Antibiotic-resistant Pseudomonas aeruginosa Bloodstream Infection in Adult Patients With Acute Leukemia.
    Zhao Y; Lin Q; Liu L; Ma R; Chen J; Shen Y; Zhu G; Jiang E; Mi Y; Han M; Wang J; Feng S
    Clin Infect Dis; 2020 Dec; 71(Suppl 4):S386-S393. PubMed ID: 33367574
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Carbapenem-resistant
    Huang W; Wei X; Xu G; Zhang X; Wang X
    Front Public Health; 2023; 11():1088262. PubMed ID: 36844819
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ceftazidime-avibactam and ceftolozane-tazobactam susceptibility of multidrug resistant Pseudomonas aeruginosa strains in Hungary.
    O'Neall D; Juhász E; Tóth Á; Urbán E; Szabó J; Melegh S; Katona K; Kristóf K
    Acta Microbiol Immunol Hung; 2020 Mar; 67(1):61-65. PubMed ID: 32208923
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Relationship of carbapenem restriction in 22 university teaching hospitals to carbapenem use and carbapenem-resistant Pseudomonas aeruginosa.
    Pakyz AL; Oinonen M; Polk RE
    Antimicrob Agents Chemother; 2009 May; 53(5):1983-6. PubMed ID: 19273670
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Changes in the incidences of multidrug-resistant and extensively drug-resistant organisms isolated in a military medical center.
    Keen EF; Murray CK; Robinson BJ; Hospenthal DR; Co EM; Aldous WK
    Infect Control Hosp Epidemiol; 2010 Jul; 31(7):728-32. PubMed ID: 20500036
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients.
    Peña C; Guzmán A; Suarez C; Dominguez MA; Tubau F; Pujol M; Gudiol F; Ariza J
    Antimicrob Agents Chemother; 2007 Jun; 51(6):1967-71. PubMed ID: 17420207
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immediate and later impacts of antimicrobial consumption on carbapenem-resistant Acinetobacter spp., Pseudomonas aeruginosa, and Klebsiella spp. in a teaching hospital in Brazil: a 10-year trend study.
    Federico MP; Furtado GH
    Eur J Clin Microbiol Infect Dis; 2018 Nov; 37(11):2153-2158. PubMed ID: 30112695
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Reduction in fluoroquinolone use following introduction of ertapenem into a hospital formulary is associated with improvement in susceptibility of Pseudomonas aeruginosa to group 2 carbapenems: a 10-year study.
    Cook PP; Gooch M; Rizzo S
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5597-601. PubMed ID: 21968357
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Urinary tract infections caused by Pseudomonas aeruginosa among children in Southern Poland: Virulence factors and antibiotic resistance.
    Pobiega M; Maciag J; Pomorska-Wesolowska M; Chmielarczyk A; Romaniszyn D; Ziolkowski G; Heczko PB; Wojkowska-Mach J; Bulanda M
    J Pediatr Urol; 2016 Feb; 12(1):36.e1-6. PubMed ID: 26320394
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Multidrug-resistant Pseudomonas aeruginosa lower respiratory tract infections in the intensive care unit: Prevalence and risk factors.
    Trinh TD; Zasowski EJ; Claeys KC; Lagnf AM; Kidambi S; Davis SL; Rybak MJ
    Diagn Microbiol Infect Dis; 2017 Sep; 89(1):61-66. PubMed ID: 28716451
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Relationship between the usage of carbapenem antibiotics and the incidence of imipenem-resistant Pseudomonas aeruginosa.
    Fujimura S; Nakano Y; Sato T; Shirahata K; Watanabe A
    J Infect Chemother; 2007 Jun; 13(3):147-50. PubMed ID: 17593500
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Incidence, antimicrobial resistance and mortality of
    Xiao S; Liang X; Han L; Zhao S
    Front Public Health; 2023; 11():1294141. PubMed ID: 38249405
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vitro activities of ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam and other comparators against Pseudomonas aeruginosa isolates with discrepant resistance to carbapenems: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2012-2021.
    Lee YL; Ko WC; Hsueh PR
    Int J Antimicrob Agents; 2023 Aug; 62(2):106867. PubMed ID: 37244423
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999.
    Gales AC; Jones RN; Turnidge J; Rennie R; Ramphal R
    Clin Infect Dis; 2001 May; 32 Suppl 2():S146-55. PubMed ID: 11320454
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000).
    Jones RN; Kirby JT; Beach ML; Biedenbach DJ; Pfaller MA
    Diagn Microbiol Infect Dis; 2002 Jul; 43(3):239-43. PubMed ID: 12106958
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa collected in the Study for Monitoring Antimicrobial Resistance Trends (SMART) between 2016 and 2019 in China.
    Yu W; Zhang H; Zhu Y; Jia P; Xu Y; Yang Q
    Int J Antimicrob Agents; 2023 Apr; 61(4):106741. PubMed ID: 36736928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.